US 12,433,880 B2
Methods for the treatment of neurological disorders
Benjamin Matteson Vincent, Cambridge, MA (US); Daniel Forrest Tardiff, Arlington, MA (US); Jeff Scott Piotrowski, Somerville, MA (US); Eric Solis, Milford, MA (US); Robert Hughie Scannevin, Hopkinton, MA (US); Chee-Yeun Chung, Brookline, MA (US); Rebecca Aron, Cambridge, MA (US); Bertrand Le Bourdonnec, Northborough, MA (US); Matthew Lucas, Lexington, MA (US); and Kenneth Rhodes, Belmont, MA (US)
Assigned to JANSSEN PHARMACEUTICA NV, Beerse (BE)
Filed by JANSSEN PHARMACEUTICA NV, Beerse (BE)
Filed on Apr. 9, 2021, as Appl. No. 17/226,233.
Application 17/226,233 is a continuation of application No. 15/863,773, filed on Jan. 5, 2018, granted, now 10,973,810, issued on Apr. 13, 2021.
Claims priority of provisional application 62/443,066, filed on Jan. 6, 2017.
Prior Publication US 2022/0040167 A1, Feb. 10, 2022
Int. Cl. A61P 25/14 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 45/06 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); G01N 33/68 (2006.01)
CPC A61K 31/454 (2013.01) [A61K 31/4545 (2013.01); A61K 45/06 (2013.01); A61P 25/14 (2018.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01); G01N 33/6896 (2013.01); G01N 2333/46 (2013.01); G01N 2333/775 (2013.01); G01N 2800/28 (2013.01); G01N 2800/2814 (2013.01); G01N 2800/2821 (2013.01); G01N 2800/2828 (2013.01); G01N 2800/2835 (2013.01); G01N 2800/285 (2013.01)] 23 Claims
 
1. A method of treating a neurological disorder in a subject in need thereof, the method comprising administering an SCD inhibitor in an amount sufficient to suppress toxicity in a cell related to protein misfolding or aggregation, wherein the SCD inhibitor is selected from the group consisting of:

OG Complex Work Unit Chemistry